[1] Wang A Y, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease [J]. Clin Nutr, 2019, 38(3): 975-981.
[2] Liebe R, Esposito I, Bock H H, et al. Diagnosis and management of secondary causes of steatohepatitis [J]. J Hepatol, 2021, 74(6): 1455-1471.
[3] Younes R, Bugianesi E. NASH in Lean Individuals [J]. Semin Liver Dis, 2019, 39(1): 86-95.
[4] Semmler G, Wernly S, Bachmayer S, et al. Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study [J]. Clin Transl Gastroenterol, 2021, 12(4): e00326.
[5] Hagstr?m H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study [J]. Hepatol Commun, 2018, 2(1): 48-57.
[6] Hussain M M, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly [J]. J Lipid Res, 2003, 44(1): 22-32.
[7] Nakajima K, Nagamine T, Fujita M, et al. Apolipoprotein B-48: a unique marker of chylomicron metabolism [J]. Adv Clin Chem, 2014, 64: 117-177.
[8] Rodríguez de Vera-Gómez P, Del Pino-Bellido P, García-González J J, et al. Novel APOB nonsense variant related to familial hypobetalipoproteinemia and hepatic steatosis: a case report and review [J]. J Clin Lipidol, 2022, 16(5): 601-607.
[9] Vanhoye X, Janin A, Caillaud A, et al. APOB CRISPR-Cas9 engineering in hypobetalipoproteinemia: a promising tool for functional studies of novel variants [J]. Int J Mol Sci, 2022, 23(8):4281.
[10] Linton M F, Farese R V Jr, Young S G. Familial hypobetalipoproteinemia [J]. J Lipid Res, 1993, 34(4): 521-541.
[11] 郭海军. 肝脾肿大伴β脂蛋白缺乏症1例报告 [J]. 临床肝胆病杂志, 2022, 38(08): 1880-1882.
[12] Di Filippo M, Moulin P, Roy P, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia [J]. J Hepatol, 2014, 61(4): 891-902.
[13] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology [J]. Genet Med, 2015, 17(5): 405-424.
[14] Di Costanzo A, Di Leo E, Noto D, et al. Clinical and biochemical characteristics of individuals with low cholesterol syndromes: a comparison between familial hypobeta-lipoproteinemia and familial combined hypolipidemia [J]. J Clin Lipidol, 2017, 11(5): 1234-1242.
[15] Burnett J R, Hooper A J, Hegele R A. APOB-related familial hypobetalipoproteinemia [M/OL](2021-09-09) [2024-04-10]https://www.ncbi.nlm.nih.gov/books/NBK570370/.
[16] Welty F K. Hypobetalipoproteinemia and abetalipoproteinemia [J]. Curr Opin Lipidol, 2014, 25(3): 161-168.
[17] Gong A, Leitold S, Uhanova J, et al. Non-Wilson’s disease-associated hypoceruloplasminemia [J]. J Clin Exp Hepatol, 2020, 10(4): 284-289.
[18] Nishioji K, Mochizuki N, Kobayashi M, et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain ≥10 kg after age 20 on non-alcoholic fatty liver disease in non-obese japanese individuals [J]. PLoS One, 2015, 10(10): e0140427. |
